Tesamorelin

Peptoris Labs

Tesamorelin

£40.00

Plan your course

Not sure of the dose? Use the figure from this product's research protocol and choose whether it is per day or per week below.

Dose Frequency Course length

— vial(s) needed at — vial size

Estimate only — based on a steady dose at your chosen frequency and selected vial size. Titration may use less in early weeks. For research use only, not medical advice.

Description

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid modification. Marketed under the brand name Egrifta®, tesamorelin is the only GHRH analog currently FDA-approved for therapeutic use—specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Unlike direct growth hormone administration, tesamorelin stimulates the pituitary gland to produce and release endogenous GH, maintaining physiological feedback mechanisms. Beyond its approved indication, tesamorelin is being actively researched for applications in non-alcoholic fatty liver disease (NAFLD), cognitive function in aging, and metabolic health optimization.

Certificate of Analysis

Every batch of Tesamorelin is independently lab-tested to a minimum of 98% purity. A Certificate of Analysis is available on request — contact us with your order or lot number and we'll send the COA for your specific batch.

Request a COA

For laboratory and research use only. Minimum 98% purity. Supplied in sterile, flip-top headspace vials for laboratory use. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. The purchaser accepts full responsibility for safe handling, storage and lawful use.